Lutropin alfa

Drugs

Volumn 68, Issue 11, 2008, Pages 1529-1540

  Dhillon, Sohita ^a,b   Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Profiles; Female infertility; Lutropin alfa, general

Indexed keywords

CHORIONIC GONADOTROPIN; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; PERGOVERIS; PLACEBO; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE;

ABDOMINAL PAIN; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; HEADACHE; HORMONE DEFICIENCY; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; INFERTILITY THERAPY; MASTALGIA; NAUSEA; OVARY CYST; OVARY HYPERSTIMULATION; REVIEW; SINGLE DRUG DOSE;

DRUG THERAPY, COMBINATION; FEMALE; FERTILITY AGENTS, FEMALE; FOLLICLE STIMULATING HORMONE, HUMAN; GLYCOPROTEIN HORMONES, ALPHA SUBUNIT; HUMANS; HYPOGONADISM; INFERTILITY, FEMALE; INJECTIONS, SUBCUTANEOUS; LUTEINIZING HORMONE; OVULATION INDUCTION; RECOMBINANT PROTEINS;

EID: 47349088932     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868110-00005     Document Type: Review

References (50)

1. Serono S.A. Infertility in females [online]. Available from URL: http://www.fertility.com [Accessed 2006 Feb 1]
2. Hugues J. Current practices and controversies in assisted reproduction: ovarian stimulation for assisted reproduction technologies [online]. Available from URL: http://www.who.int/reproductive-health/infertility/report_content.htm [Accessed 2006 Feb 1]
3. Filicori M. Gonadotropin-releasing hormone analogs in ovulation induction: current status and perspectives. J Clin Endocrinol Metab 1996; 81 (7): 2413-6
4. Burgues S. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain. Hum Reprod 2001; 16: 2525-32
5. European Recombinant Human LHStudyGroup. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab 1998; 83: 1507-14
6. Filicori M, Flamigni C, Dellai P, et al. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab 1994; 79 (4): 1215-20
7. The ESHRE Capri Workshop Group. Anovulatory infertility. Hum Reprod 1995; 10 (6): 1549-53
8. Guidice E, Crisci C, Altarocca V, et al. Characterization of a partially purified human menopausal gonadotropin preparation. J Drug Assess 2001; 4 (3): 171-8
9. Baer G, Loumaye E. Comparison of recombinant human luteinising hormone (r-hLH) and human menopausal gonadotropin (hMG) in assisted reproductive technology. Curr Med Res Opin 2003; 19 (2): 83-8
10. Rodgers M, Mitchell R, Lambert A, et al. Human chorionic gonadotropin contributes to the bioactivity of pergonal. Clin Endocrinol (Oxf) 1992; 37: 558-64
11. Filicori M, Cognigni G. Roles and novel regimens of luteinizing hormone and follicle stimulating hormone in ovulation induction. J Clin Endocrinol Metab 2001; 86 (4): 1437-41
12. Alviggi C, Clarizia R, Mollo A, et al. Outlook: who needs LH in ovarian stimulation? Reprod Biomed Online 2006 May; 12 (5): 599-607
13. Alviggi C, Mollo A, Clarizia R, et al. Exploiting LH in ovarian stimulation. Reprod Biomed Online 2006 Feb; 12 (2): 221-33
14. Serono International SA. FDA Approves Serono's Luveris® for concomitant use with Gonal-f® [media release]. 2004 Oct 15
15. Serono. Luveris (lutropin for injection) for subcutaneous use: prescribing information [online]. Available from URL: http://www.fda.gov/cder/ foi/label/2004/21322lbl.pdf [Accessed 2008 Mar 26]
16. Ludwig M. Does the addition of luteinizing hormone in ovarian stimulation protocols improve the outcome? Treat Endocrinol 2003; 2 (5): 305-13
17. European Medicines Agency. Summary of product characteristics: pergoveris 150 IU/75 IU [online]. Available from URL: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/pergoveris/H-714-PI-en.pdf [Accessed 2008 Apr 23]
18. Serono Europe Limited. Luveris: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ Luveris/H-292-PI-en.pdf [Accessed 2008 Mar 26]
19. Filicori M, Cognigni GE, Samara A, et al. The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction. Hum Reprod Update 2002; 8 (6): 543-57
20. O'Dea L. Recombinant LH in support of recombinant FSH in female hypogonadotropic hypogonadism: evidence of threshold effect [abstract no. O-093]. The US Recombinant Human L H Study Group. Fertil Steril 2000; 74 (3 Suppl. 1): S36
21. Hemsey F, O'Brien L, O'Dea L. Objective evidence of LH-dependence in women with profound LH and FSH deficiency [abstract no. P-292]. Fertil Steril 2001; 76 (3 Suppl. 1): S208
22. Kaufmann R, Dunn R, Vaughn T, et al. Recombinant human luteinizing hormone, lutropin alfa, for the induction of follicular development and pregnancy in the profoundly gonadotrophin-deficient women. Clin Endocrinol (Oxf) 2007; 67: 563-9
23. Loumaye E, Engrand P, Shoham Z, et al. Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod 2003; 18: 314-22
24. Hugues J, Soussis J, Calderon I, et al. Does the addition of recombinant LH in WHO group II anovulatory women overresponding to FSH treatment reduce the number of developing follicles? A dose finding study. Hum Reprod 2005; 20 (3): 629-35
25. Ruvolo G, Bosco L, Pane A, et al. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertil Steril 2007; 87 (3): 542-6
26. De Placido G, Mollo A, Clarizia R, et al. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patient at risk for poor ovarian response. Fertil Steril 2006 Jan; 85 (1): 247-50
27. le Cotonnec JY, Porchet HC, Beltrami V, et al. Clinical pharmacology of recombinant human luteinizing hormone: part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. Fertil Steril 1998; 69: 189-94
28. le Cotonnec JY, Loumaye E, Porchet HC, et al. Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. Fertil Steril 1998; 69: 201-9
29. le Cotonnec JY, Porchet HC, Beltrami V, et al. Clinical pharmacology of recombinant human luteinizing hormone: part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. Fertil Steril 1998; 69: 195-200
30. Kousta E, White DM, Piazzi A, et al. Successful induction of ovulation and completed pregnancy using recombinant human luteinizing hormone and follicle stimulating hormone in a woman with Kallmann's syndrome. Hum Reprod 1996; 11 (1): 70-1
31. Hull M, Corrigan E, Piazzi A, et al. Recombinant human luteinising hormone: an effective new gonadotropin preparation. Lancet 1994; 344: 334-5
32. Balasch J, Fabregues F. Pregnancy after administration of high dose recombinant human LH alone to support final stages of follicular maturation in a woman with long-standing hypogonadotrophic hypogonadism. Reprod Biomed Online 2003; 6 (4): 427-31
33. Lisi F, Rinaldi L, Fishel S, et al. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril 2005 Feb; 83 (2): 309-15
34. Sills ES, Levy DP, Moomjy M, et al. A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization. Hum Reprod 1999; 14: 2230-5
35. Balasch J, Creus M, Fabregues F, et al. The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction. J Assist Reprod Genet 2001; 18: 250-6
36. Weigert M, Krischker U, Pohl M, et al. Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study. Fertil Steril 2002; 78 (1): 34-9
37. Humaidan P, Bungum M, Bungum L, et al. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online 2004; 8 (6): 635-43
38. Marrs R, Meldrum D, Muasher S, et al. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online 2004; 8 (2): 175-82
39. Griesinger G, SchultzeMosgau A, Dafopoulos K, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum Reprod 2005; 20 (5): 1200-6
40. Tarlatzis B, Tavmergen E, Szamatowicz M, et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. Hum Reprod 2006 Jan; 21 (1): 90-4
41. NyboeAndersen A, Humaidan P, Fried G, et al. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization: a multicentre, prospective, randomized, controlled trial. Hum Reprod 2008; 23 (2): 427-34
42. Sauer MV, Thornton 2nd MH, Schoolcraft W, et al. Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reprod Biomed Online 2004 Nov; 9 (5): 487-93
43. Levi-Setti PE, Cavagna M, Bulletti C. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH. Eur J Obstet Gynecol Reprod Biol 2006 Jun 1; 126 (2): 212-6
44. Barrenetxea G, Agirregoikoa JA, Jiménez MR, et al. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertil Steril 2008; 89 (3): 546-53
45. Mochtar MH, Van der Veen F, Ziech M, et al. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles (review). Cochrane Database Syst Rev 2007 Apr 18; (2): CD005070
46. DePlacido G, Alviggi C, Perino A, et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH: a multicentre, prospective, randomized controlled trial. Hum Reprod 2005; 20 (2): 390-6
47. Ferraretti AP, Gianaroli MD, Magli MC, et al. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004; 82 (6): 1521-6
48. Fabregues F, Creus M, Penarrubia J, et al. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil Steril 2006; 85 (4): 925-31
49. Lisi F, Rinaldi L, Fishel S, et al. Use of recombinant LH in a group of unselected IVF patients. Reprod Biomed Online 2002; 5 (2): 104-8
50. De Placido G, Alviggi C, Mollo A, et al. Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulation. Clin Endocrinol (Oxf) 2004 May; 60 (5): 637-43